Follow us on Twitter
Immune Diseases patents
This page is updated frequently with new Immune Diseases-related patents. Subscribe to the Immune Diseases RSS feed to automatically get the update: related Immune RSS feeds.
|| List of recent Immune Diseases-related patents
|Compounds and methods for treating autoimmune diseases|
The invention relates to a compound of formula i:. .
|Administration of interferon for prophylaxis against or treatment of pathogenic infection|
The invention provides compositions and methods for the prophylaxis or treatment of diseases or disorders in a subject (e.g., a mammal, such as a human) including, e.g., diseases or disorders caused by biological agents, autoimmune diseases, and cancer. The compositions include a delivery vector (e.g., a viral vector, such as an ad5 vector) encoding an interferon (e.g., ifn-α), and are provided to the subject by, e.g., intranasal or pulmonary administration..
|Use of cytokines and mitogens to inhibit pathological immune responses|
The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.. .
|Abcb5 positive mesenchymal stem cells as immunomodulators|
The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the abcb5 p-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used.
|Use of arsenic compounds for treatment of pain and inflammation|
The present invention relates to the use of arsenic compounds such as sodium meta arsenite (naaso2), arsenic trioxide (as2o3), and arsenic hexoxide (as4o6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders..
|Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases|
Methods are disclosed for treating or inhibiting an autoimmune disease in a subject. In some embodiments, the disclosed methods include administering to the subject a therapeutically effective amount of one or more major histocompatibility complex (mhc) molecules including covalently linked first, second and third domains; wherein the first domain is an mhc class ii β1 domain and the second domain is an mhc class ii α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an mhc class i α1 domain and the second domain is an mhc class i α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen associated with the autoimmune disorder.
|Novel biaromatic compounds that modulate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof|
And cosmetic/pharmaceutical compositions comprised thereof are useful in human or veterinary medicine (in dermatology and also in the fields of cardiovascular diseases, of immune diseases and/of diseases related to the metabolism of lipids), or, alternatively, in cosmetic compositions.. .
|Novel compounds useful for the treatment of metabolic and inflammatory diseases|
These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.. .
|Compositions and methods for the prevention and treatment of autoimmune conditions|
The methods include selectively reducing or expanding t cells according to the antigenic specificity of the t cells. Therefore, the present invention can be used to reduce or eliminate pathogenic t cells that recognize autoantigens, such as beta cell specific t cells.
|Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism|
An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.
|Trihydroxy polyunsaturated eicosanoid derivatives|
The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods.
|Composition for improving membrane composition and functioning of cells|
The health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery..
|Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and use in therapy|
Improved anti-cd154 antibodies are provided herein which have ablated fcr binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein..
|Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor|
The present invention is based, in part, on the identification of novel human anti-pd-1, pd-l1, and pd-l2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating pd-1, pd-l1, and/or pd-l2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-pd-1, pd-l1, and pd-l2 antibodies described herein..
|Fibronectin based scaffold domain proteins that bind il-23|
The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (il-23). The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases.
|Methods for the treatment or prevention of systemic sclerosis|
The invention is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The invention is based on the observation that ssc patients have an elevated plasma level of cxcl4.
|Combination therapy for treatment of immune disorders|
Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of il-23 is continued for a longer time to prevent recurrence of the acute event.
|Antigen-specific, tolerance-inducing microparticles and uses thereof|
The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time.
|Method for identifying biologically active oligonucleotides capable of modulating the immune system|
The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer..
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Manipulation of hsp70 and ire1alpha protein interactions|
The present invention relates to methods that manipulate the level of interaction between the proteins hsp70 and ire1α. In particular, the invention relates to methods of manipulating this interaction in order to increase protein yield, and to methods of manipulating this interaction in order to treat diseases associated with abnormal apoptotic activity, including cancer and autoimmune diseases..
|Estriol therapy for multiple sclerosis and other autoimmune diseases|
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..
Popular terms: [SEARCH]
Immune Diseases topics: Immune Diseases, Autoimmune, Immune Disease, Autoimmune Disease, Autoimmune Diseases, Immune Disorder, Rheumatoid Arthritis, Antibodies, Antagonist, Nucleotide, Proliferative, Infectious, Infectious Disease, Infectious Diseases, Type 1 Diabetes
Follow us on Twitter
This listing is a sample listing of patents related to Immune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.